Supplementary Online Content


eFigure. Comparisons of overall response rates (ORR) to irinotecan- and oxaliplatin-containing regimens administered in first line
eReferences.

This supplementary material has been provided by the authors to give readers additional information about their work.
**eFigure 1:** Comparisons of overall response rates (ORR) to irinotecan and oxaliplatin-containing regimens administered in first line

The ORRs in first line are less when these regimens were administered as the control regimens, more so for irinotecan- than for oxaliplatin-containing regimens.


94. Venook et al. CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC). J Clin Oncol 32:5s, 2014 (suppl; abstr LBA3)